Page 31 - San Antonio Breast Cancer Symposium News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dato-DXd Deemed New Treatment Option for HR+, HER2- Advanced Breast Cancer

Dato-DXd improved outcomes over chemotherapy in a phase 3 trial of patients with previously treated, inoperable or metastatic, HR+, HER2- breast cancer. Dato-DXd improved outcomes over chemotherapy in a phase 3 trial of patients with previously treated, inoperable or metastatic, HR+, HER2- breast cancer.

San antonioUnited statesAditya bardiaSan antonio breast cancer symposiumMassachusetts general hospital

Potentially targetable fusion RNAs may be more common in metastatic breast cancer than previously realized

Potentially targetable fusion RNAs may be more common in metastatic breast cancer than previously realized
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesNolan priedigkeitTodd golubBroad instituteHarvard medical schoolDana farber cancer instituteSan antonio breast cancer symposiumHuman cancer genetics

Some breast cancer survivors may safely de-escalate mammography three years after surgery

Some breast cancer survivors may safely de-escalate mammography three years after surgery
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesJanet dunnUniversity of warwickSan antonio breast cancer symposium

Chemo-Free Regimen May Be Frontline Option for HR+, HER2+ Metastatic Breast Cancer

Anastrozole plus palbociclib, trastuzumab, and pertuzumab may provide a chemotherapy-free frontline treatment option for HR+, HER2+ metastatic breast cancer. Anastrozole plus palbociclib, trastuzumab, and pertuzumab may provide a chemotherapy-free frontline treatment option for HR+, HER2+ metastatic breast cancer.

New yorkUnited statesSan antonioAmy tierstenSan antonio breast cancer symposiumMount sinai

Bilateral Mastectomy Did Not Decrease Risk of Death in Breast Cancer Patients With BRCA1 Mutations

Undergoing a bilateral mastectomy does not appear to decrease the risk of death in breast cancer patients who have a BRCA1 pathogenic variant. Undergoing a bilateral mastectomy does not appear to decrease the risk of death in breast cancer patients who have a BRCA1 pathogenic variant.

San antonioUnited statesKellya metcalfeUniversity of torontoSan antonio breast cancer symposium